BACKGROUND: Quality of life (QOL) and physical condition (PC) outcomes after sentinel lymph node biopsy (SLNB), @entity1600 ( @entity1600 ), and adjuvant therapy with interferon alfa-2b (IFN) were evaluated in this study. METHODS: Self-reported QOL and PC scores were evaluated in @entity1 enrolled in a prospective, multicenter, randomized, clinical trial evaluating adjuvant IFN. After SLN biopsy, @entity1 with a positive SLN underwent @entity1600 then were randomized to adjuvant IFN or observation. QOL and PC scores were compared between @entity1 who underwent SLNB alone, @entity1600 without IFN, and @entity1600 with IFN. Time to return to baseline QOL and PC scores reported at the time of SLNB was recorded and compared. RESULTS: There were statistically significant differences in time to return to baseline QOL (p  =  0.0018) and PC (p  =  0.0018) scores across the three treatment groups. The time to return to baseline QOL and PC scores was similar for SLND and @entity1600 alone. Differences in time to return to baseline QOL and PC were sustained when stratified by recurrence status but did not differ significantly for different lymph node regions. There was a delay in @entity558 scores that was sustained beyond the cessation of IFN therapy. CONCLUSIONS: @entity1600 is well-tolerated with a similar effect on self-reported QOL outcomes in both the short- and long-term compared with SLNB alone. IFN therapy is associated with worse QOL outcomes compared with SLNB and @entity1600 , an effect that may be sustained following cessation of adjuvant IFN.

Melanoma XXXX -Reported Quality of Life Outcomes Following Sentinel Lymph Node Biopsy, Completion Lymphadenectomy, and Adjuvant Interferon: Results from the Sunbelt Melanoma Trial.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity558 :: ('MESH:C536528', 'Disease') :: ['return to baseline QOL and PC condition'] @entity1600 :: ('MESH:D014388', 'Disease') :: ['completion lymph node dissection', 'CLND']
@entity1 :: (9606,Species) :: ['Patient']
